ESR1 and breast carcinoma: In this subgroup analysis, U6, but not 5S, levels were higher in the sera of patients with ER/PR+ breast cancer compared with healthy subjects with or without normalization with miR-16 and SNORD44 (Table 5 and Figure 3).